The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) has entered into agreements to purchase The Eyecare Place, an optical store located in Abbotsford, Victoria
  • The company will purchase the store in a cash-and-scrip deal worth $620,000
  • Settlement is conditional upon assignment of the property leased to Healthia and other customary conditions
  • Additionally, Healthia has also completed the purchase of Bernie Lanigan Optometrist, an optical store located in Townsville, Queensland
  • On the market today, Healthia is trading in the grey at $1.76 per share

Healthia (HLA) has entered into agreements to purchase The Eyecare Place, an optical store located in Abbotsford, Victoria.

The company will purchase the store in a cash-and-script deal worth $620,000.

The Eyecare Place was founded in 2010 and is located in the Hive Shopping Centre, a community shopping centre in Abbotsford, Victoria, which is anchored by major retailers.

Settlement is conditional upon assignment of the property leased to Healthia and other customary conditions.

Additionally, Healthia has also completed the purchase of Bernie Lanigan Optometrist, an optical store located in Townsville, Queensland.

For over 42 years Bernie Lanigan has been providing professional eyecare and eyewear to the Townsville community.

Earlier this year, Healthia agreed to purchase Sandringham Sports Physio in Victoria for $1.5 million.

Sandringham is a physiotherapy clinic that provides services to the Sandringham and Bayside community.

On the market today, Healthia is trading in the grey at $1.76 per share at 12:22 pm AEST.

HLA by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…